Study guide

10.4 Dermatologic, Metabolic & Fatigue Management

Advanced Oncology Certified Nurse Practitioner AOCNP

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & Exam Overview

1.1 About the AOCNP Exam 1.2 How to Use This AOCNP Study Guide

2 Chapter 2: Cancer Continuum - Risk, Prevention & Screening

2.1 Cancer Risk Factors, At-Risk Populations & Health Disparities 2.2 Primary Prevention, Vaccination, Chemoprevention & Risk-Reducing Surgery 2.3 Cancer Screening & Early Detection Guidelines 2.4 Screening for Subsequent & Second Primary Malignancies 2.5 Hereditary Cancer Syndromes & Genetic Counseling

3 Chapter 3: Cancer Continuum - Assessment, Diagnosis & Staging

3.1 Diagnostic Workup, Tissue Biopsy & Biomarker Evaluation 3.2 Pathology Interpretation, Histology & Tumor Grading 3.3 Cancer Staging Systems (TNM) & Prognostication Models 3.4 Performance Status, Frailty & Geriatric Assessment

4 Chapter 4: Cancer Continuum - Planning, Coordination & Survivorship

4.1 Established Guidelines for Care & Categories of Evidence 4.2 Individualized Treatment Planning & Molecular Tumor Boards 4.3 Reproductive Planning & Fertility Preservation 4.4 Patient Navigation & Interprofessional Care Coordination 4.5 Survivorship Care Planning & Late Effects Management 4.6 Post-Treatment Surveillance for Cancer Recurrence

5 Chapter 5: Cancer Treatment - Antineoplastic Pharmacology & Chemotherapy

5.1 Antineoplastic Principles, Dosing & Dose Adjustments 5.2 Cytotoxic Chemotherapy Classes & Adverse Effect Management 5.3 Safe Administration, Handling & Infusion Toxicities 5.4 Oral Antineoplastic Therapy: Adherence, Interactions & Monitoring

6 Chapter 6: Cancer Treatment - Targeted, Immuno & Hormonal Therapies

6.1 Targeted Therapies, Tyrosine Kinase Inhibitors & ADCs 6.2 Cancer Immunotherapy, Checkpoint Inhibitors & CAR T-Cell Therapy 6.3 Endocrine & Hormonal Therapies in Oncology

7 Chapter 7: Cancer Treatment - Radiation, Surgery, Regional & Multimodal Therapy

7.1 Radiation Oncology Principles & Toxicity Management 7.2 Surgical Oncology, Perioperative Care & Reconstruction 7.3 Regional & Localized Therapy Administration 7.4 Multimodal Therapy & Treatment Sequencing 7.5 Complementary, Alternative & Integrative Therapies

8 Chapter 8: Cancer Treatment - Transplantation, Clinical Trials & Response

8.1 Hematopoietic Stem Cell Transplantation (HSCT) & Cell Therapy 8.2 Clinical Trials, Research Protocols & Response Evaluation (RECIST)

9 Chapter 9: Supportive Care - Pain & Controlled Substance Safety

9.1 Cancer Pain Assessment & Comprehensive Analgesic Management 9.2 Controlled Substance Safety & Opioid Stewardship 9.3 Nonpharmacologic & Integrative Symptom Interventions

10 Chapter 10: Supportive Care - Symptom & Comorbidity Management

10.1 Acute, Late & Long-Term Patterns of Treatment-Related Symptoms 10.2 Gastrointestinal Symptom Management (CINV, Mucositis, Diarrhea) 10.3 Hematologic & Neurologic Toxicity Management 10.4 Dermatologic, Metabolic & Fatigue Management 10.5 Cancer-Associated Thrombosis & Anticoagulation 10.6 Comorbid Conditions & Their Interaction With Cancer Treatment 10.7 Palliative Care, Hospice & End-of-Life Management

11 Chapter 11: Oncologic Emergencies

11.1 Superior Vena Cava Syndrome & Structural Emergencies 11.2 Spinal Cord Compression & Neurologic Emergencies 11.3 Metabolic Emergencies: Tumor Lysis Syndrome & Hypercalcemia of Malignancy 11.4 Febrile Neutropenia, Sepsis & Vesicant Extravasation 11.5 Cardiopulmonary & Airway Emergencies 11.6 Hematologic & Endocrine Emergencies: DIC, Leukostasis, Hyperviscosity & SIADH

12 Chapter 12: Psychosocial Issues

12.1 Psychosocial Assessment & Distress Screening in Oncology 12.2 Risk Factors & At-Risk Oncology Populations 12.3 Psychosocial & Emotional Sequelae of Disease and Treatment 12.4 Psychiatric & Psychosocial Comorbidities in Cancer Care 12.5 Caregiver Burden, Support & Community Resources

13 Chapter 13: Professional Practice & Roles of the APRN

13.1 APRN Scope of Practice, Prescriptive Authority & Standards of Care 13.2 Bioethics, Informed Consent & Quality Improvement in Oncology 13.3 Cultural Competence, Implicit Bias & Equitable Oncology Care 13.4 Accreditation Standards & Outcomes of APRN Practice 13.5 Competency Evaluation, Peer Review & Peer Education

10.4 Dermatologic, Metabolic & Fatigue Management

Key Takeaways Explain This Topic AI

EGFR inhibitor papulopustular acneiform rash occurs in 70-90% of patients and correlates positively with tumor response; primary prevention requires oral doxycycline/minocycline plus topical hydrocortisone 1%.

Hand-Foot Skin Reaction (HFSR) from multi-kinase inhibitors presents as localized hyperkeratotic lesions on pressure points, whereas Hand-Foot Syndrome (PPE) from capecitabine/5-FU causes diffuse palmar-plantar erythema.

Immune checkpoint inhibitor (ICI) severe dermatologic irAEs (Grade 3-4) require withholding immunotherapy and initiating high-dose systemic corticosteroids (prednisone 1-2 mg/kg/day) with a 4-6 week taper.

Cancer-related fatigue (CRF) must be screened universally; aerobic and resistance exercise holds Level 1 evidence as the most effective non-pharmacological intervention.

Cancer Anorexia-Cachexia Syndrome (CACS) involves pro-inflammatory cytokine muscle wasting; megestrol acetate improves appetite and weight but carries high deep vein thrombosis (DVT/PE) risks, whereas dexamethasone provides rapid short-term benefit.

Last updated: August 2026

Dermatologic, Metabolic & Fatigue Management

Modern targeted therapies, immune checkpoint inhibitors (ICIs), and cytotoxic agents produce unique non-hematologic toxicities that significantly impact quality of life, functional status, and treatment adherence. Advanced Practice Registered Nurses (APRNs) must master the prevention and management of targeted dermatologic eruptions, severe cutaneous immune-related adverse events (irAEs), Cancer-Related Fatigue (CRF), and Cancer Anorexia-Cachexia Syndrome (CACS).

1. EGFR Inhibitor & Targeted Cutaneous Toxicities

Epidermal Growth Factor Receptor (EGFR) inhibitors (monoclonal antibodies: Cetuximab, Panitumumab; small molecule TKIs: Erlotinib, Afatinib, Osimertinib) disrupt EGFR signaling in epidermal keratinocytes, causing follicular occlusion, inflammation, and severe skin toxicity.

EGFR-Induced Papulopustular Acneiform Rash

Incidence & Significance : Occurs in 70% to 90% of patients within the first 1 to 2 weeks of therapy. Crucially, the severity of the rash correlates positively with anti-tumor efficacy and overall survival .

Clinical Presentation : Follicular papules and pustules appearing primarily in seborrheic areas (face, scalp, upper chest, back). Unlike acne vulgaris, comedones are absent.

Prophylactic Management Protocol (STEP Study Evidence) : Initiate prophylaxis on Day 1 of EGFR inhibitor therapy:

Oral Tetracycline Antibiotic : Doxycycline 100 mg PO BID or Minocycline 100 mg PO BID for the first 6 to 8 weeks (provides anti-inflammatory, not antibacterial, action).

Topical Corticosteroid : Hydrocortisone 1% cream applied to face and trunk daily.

Skin Care : Alcohol-free thick emollients; broad-spectrum SPF ≥ 30 \ge 30 ≥ 30 sunscreen.

Patient Education Warning : Avoid over-the-counter drying acne washes containing benzoyl peroxide or salicylic acid, which exacerbate mucosal barrier breakdown.

2. Hand-Foot Skin Reaction (HFSR) vs Hand-Foot Syndrome (PPE)

APRNs must clinically distinguish between two distinct palmar-plantar toxicities:

Feature Hand-Foot Skin Reaction (HFSR) Hand-Foot Syndrome / Palmar-Plantar Erythrodysesthesia (PPE)

Causative Agents Multi-Kinase Inhibitors (MKIs: Sorafenib, Regorafenib, Cabozantinib, Sunitinib). Cytotoxic Chemotherapy (Capecitabine, Continuous 5-FU, Liposomal Doxorubicin).

Pathophysiology Inhibition of VEGFR and PDGFR causing microvascular capillary endothelial repair failure at friction sites. Direct cytotoxic extravasation into palmar/plantar capillaries.

Lesion Morphology Localized, thick hyperkeratotic calluses surrounded by erythematous halos on friction/pressure points (heels, metatarsal heads, palms). Diffuse, symmetric erythema, edema , and tingling/burning across entire palmar and plantar surfaces.

Management Keratolytic creams ( Urea cream 20-40% , Salicylic acid 6%); potent topical steroids ( Clobetasol 0.05% ); custom shoe insoles. Pyridoxine (Vitamin B6) 50-100 mg BID; ice packs/cooling; topical emollients; capecitabine dose reduction for Grade ≥ 2 \ge 2 ≥ 2 .

3. Immune Checkpoint Inhibitor (ICI) Cutaneous irAEs

Immune Checkpoint Inhibitors (anti-PD-1: Pembrolizumab, Nivolumab; anti-PD-L1: Atezolizumab; anti-CTLA-4: Ipilimumab) disinhibit T-cell activity, inducing autoimmune dermatologic toxicities in 30-50% of patients.

Grading & APRN Management Protocols

Grade 1 ( < 10 % <10\% < 10% Body Surface Area [BSA] maculopapular rash or pruritus): Continue ICI therapy. Apply topical low-to-medium potency corticosteroids (Triamcinolone 0.1% cream) and oral anti-pruritic antihistamines.

Grade 2 (10-30% BSA rash ± \pm ± mild ADL impact): Hold ICI temporarily. Apply high-potency topical corticosteroids (Clobetasol 0.05%). Consider oral Prednisone 0.5-1 mg/kg/day.

Grade 3-4 ( > 30 % >30\% > 30% BSA, severe blistering, or suspicion of Stevens-Johnson Syndrome [SJS] / Toxic Epidermal Necrolysis [TEN] ): Permanently discontinue ICI . Hospitalize immediately. Initiate high-dose systemic corticosteroids ( Prednisone 1 to 2 mg/kg/day IV/PO ). Taper steroids slowly over 4 to 6 weeks to prevent autoimmune rebound.

4. Cancer-Related Fatigue (CRF) & Sleep Disturbances

Cancer-Related Fatigue (CRF) is defined by NCCN as a distressing, persistent, subjective sense of physical, emotional, and/or cognitive tiredness related to cancer or cancer treatment that is not proportional to recent activity and interferes with usual functioning .

Assessment & Primary Interventions

Universal Screening : Screen every oncology patient at every contact using a 0-10 numerical rating scale (0 = no fatigue; 1-3 = mild; 4-6 = moderate; 7-10 = severe).

Rule Out Treatable Secondary Etiologies : Evaluate and treat anemia, hypothyroidism, hypogonadism, sleep apnea, uncontrolled pain, depression, electrolyte derangements, and infection.

Evidence-Based Non-Pharmacological Interventions (Gold Standard) :

Physical Exercise : Level 1 Evidence (strongest recommendation). Aerobic exercise (150 minutes/week of moderate intensity) plus resistance training significantly reduces CRF during and after treatment.

Psychosocial Interventions : Cognitive Behavioral Therapy for Insomnia (CBT-I) and energy conservation techniques.

Pharmacological Therapy for Advanced Disease : Reserve for severe, refractory CRF in patients with advanced metastatic cancer: Psychostimulants (Methylphenidate 5-10 mg PO morning and noon) or Modafinil.

5. Cancer Anorexia-Cachexia Syndrome (CACS)

Cancer Anorexia-Cachexia Syndrome (CACS) is a multifactorial metabolic syndrome characterized by involuntary loss of skeletal muscle mass (sarcopenia) with or without loss of fat mass, driven by tumor-induced systemic inflammation and catabolism (mediated by TNF- α \alpha α , IL-6, IL-1, and interferon- γ \gamma γ ). Unlike simple starvation, CACS cannot be reversed by conventional nutritional support .

Orexigenic Pharmacotherapy Comparison

Pharmacological Agent Mechanism & Primary Clinical Benefit Critical Adverse Effects & Safety Precautions

Megestrol Acetate (Progestin) Dosed at 400 mg to 800 mg PO daily . Stimulates appetite and produces modest weight gain (primarily adipose tissue and fluid retention). High Risk of Thromboembolism : Significantly increases risk of Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), peripheral edema, and adrenal suppression. Avoid in patients with history of VTE.

Dexamethasone (Corticosteroid) Dosed at 4 mg PO daily . Produces rapid improvement in appetite, energy, and sense of well-being . Limited duration of efficacy (2-4 weeks). Prolonged use causes severe proximal muscle wasting (myopathy), hyperglycemia, immunosuppression, and osteonecrosis. Best for end-of-life palliative care.

Mirtazapine Tetracyclic antidepressant (15-30 mg PO at bedtime). Enhances appetite and promotes weight gain. Beneficial dual indication for patients with concurrent depression and insomnia.

Differential Clinical Features of MKI-HFSR vs Chemotherapy-PPE